Likun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Likun Chen has a total of 409 co-authors. Here are the top co-authors by number of shared publications:
- Hongsheng Wang
Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China
29 shared publications - Jing Chen
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
28 shared publications - Chengqi Gao
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
27 shared publications - Chunhao Deng
Centre of Reproduction, Development and Aging, Faculty of Health Sciences, University of Macau, Macau SAR, China
27 shared publications - Danyang Wang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
27 shared publications - Guokai Chen
Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau
27 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1123
Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer
Background: Neuroendocrine transformation of epidermal growth factor receptor-mutant lung adenocarcinoma (EGFR m LUAD) represents a significant mechanism underlying acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). This histological transformation lacks effective treatments. We comprehensively discussed the treatments of transformed small cell lung cancer (T-SCLC) and analyzed the transcriptomic profile of EGFR m LUAD and paired T-SCLC, aiming to understand the immune landscape of this T-SCLC subtype. Methods: Patients with pathologically confirmed lung adenocarcinoma (LUAD) at baseline who subsequently developed T-SCLC confirmed by re-biopsy after antitumor therapy resistance were included. For genomic and transcriptomic profiling, paired pre- and post-transformation specimens from EGFR-mutant patients were subjected to next-generation sequencing and RNA sequencing. Additionally, we integrated gene expression data for primary SCLC (P-SCLC) from the GEO database to compare the transformed and primary SCLC types. Results: A total of 32 patients with pathologically confirmed LUAD at baseline who subsequently developed T-SCLC confirmed by re-biopsy after antitumor therapy resistance were included in this study. Among them, the median progression-free survival (mPFS) and overall survival (mOS) of T-SCLC with first-line immunotherapy plus chemotherapy were 5.1 and 21.0 months, respectively. Analysis of post-transformation treatments received after T-SCLC diagnosis revealed that patients exposed to immunotherapy had longer mOS than those who were immunotherapy-naïve (21.0 m vs. 10.0 m, P = 0.03). Our data revealed that paired T-SCLC exhibited an immune-suppressive microenvironment compared with EGFR m LUAD, which included the downregulation of multiple immune regulatory pathways, reduced immune cell infiltration, decreased scores of immune-related signatures and downregulation expression of immune checkpoint-related genes. Additionally, we found that T-SCLC exhibited a more immunologically active microenvironment than P-SCLC, as evidenced by higher scores of immune-related signatures, including MHC signature, T cell-inflamed GEP signature and IFN-gamma signature. Conclusions: The immune landscape of T-SCLC is more immunosuppressed than EGFR m LUAD, yet more immunologically active than that of P-SCLC. This immune profile provides a rationale for integrating immunotherapy with chemotherapy in T-SCLC.
- 28 August 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1123
Open AccessTranscriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer
Background: Neuroendocrine transformation of epidermal growth factor receptor-mutant lung adenocarcinoma (EGFR m LUAD) represents a significant mechanism underlying acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). This histological transformation lacks effective treatments. We comprehensively discussed the treatments of transformed small cell lung cancer (T-SCLC) and analyzed the transcriptomic profile of EGFR m LUAD and paired T-SCLC, aiming to understand the immune landscape of this T-SCLC subtype. Methods: Patients with pathologically confirmed lung adenocarcinoma (LUAD) at baseline who subsequently developed T-SCLC confirmed by re-biopsy after antitumor therapy resistance were included. For genomic and transcriptomic profiling, paired pre- and post-transformation specimens from EGFR-mutant patients were subjected to next-generation sequencing and RNA sequencing. Additionally, we integrated gene expression data for primary SCLC (P-SCLC) from the GEO database to compare the transformed and primary SCLC types. Results: A total of 32 patients with pathologically confirmed LUAD at baseline who subsequently developed T-SCLC confirmed by re-biopsy after antitumor therapy resistance were included in this study. Among them, the median progression-free survival (mPFS) and overall survival (mOS) of T-SCLC with first-line immunotherapy plus chemotherapy were 5.1 and 21.0 months, respectively. Analysis of post-transformation treatments received after T-SCLC diagnosis revealed that patients exposed to immunotherapy had longer mOS than those who were immunotherapy-naïve (21.0 m vs. 10.0 m, P = 0.03). Our data revealed that paired T-SCLC exhibited an immune-suppressive microenvironment compared with EGFR m LUAD, which included the downregulation of multiple immune regulatory pathways, reduced immune cell infiltration, decreased scores of immune-related signatures and downregulation expression of immune checkpoint-related genes. Additionally, we found that T-SCLC exhibited a more immunologically active microenvironment than P-SCLC, as evidenced by higher scores of immune-related signatures, including MHC signature, T cell-inflamed GEP signature and IFN-gamma signature. Conclusions: The immune landscape of T-SCLC is more immunosuppressed than EGFR m LUAD, yet more immunologically active than that of P-SCLC. This immune profile provides a rationale for integrating immunotherapy with chemotherapy in T-SCLC.
- Open Access
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (10) , 893-902
Izalontamab Brengitecan in Locally Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study
PURPOSE: To evaluate the safety and efficacy of izalontamab brengitecan (iza-bren) in patients with non–small cell lung cancer (NSCLC) harboring actionable genomic alterations (GAs) outside of classical epidermal growth factor receptor ( EGFR ) mutations. METHODS: Eligible patients had locally advanced or metastatic NSCLC with prespecific actionable GAs, had progressed after standard treatment and received no more than one previous line of chemotherapy. iza-bren was administered at the dose of 2.5 mg/kg once per day on days 1 and 8 of each 3-week cycle. The primary end point was safety. The secondary end points included objective response rate (ORR), disease control rate (DCR), and duration of response. The exploratory end points included progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 83 patients with NSCLC were enrolled in four cohorts: EGFR exon20ins/nonclassical mutations (n = 14), human epidermal growth factor receptor 2 ( HER2 ) mutation (n = 19), KRAS / BRAF / MET mutation (n = 26), and ALK / ROS1 / RET / NTRK fusion (n = 24). The most common grade ≥3 treatment-related adverse events (TRAEs) were thrombocytopenia (51.8%), anemia (44.6%), and neutropenia (43.4%). The most frequent nonhematologic TRAEs of all grades were nausea (49.4%), asthenia (45.8%), stomatitis (44.6%), and diarrhea (38.6%). One case of grade 2 interstitial lung disease was observed. The confirmed ORR was 39.7%, and the DCR was 85.9%. The median PFS was 7.0 months (95% CIs, 5.4 to 10.5), while OS data were immature. Patients with EGFR exon20ins or other nonclassical mutations achieved an ORR of 69.2% with a median PFS of 10.5 months (95% CI, 6.9 to not reached); the HER2 -mutant cohort had an ORR of 52.9% and a median PFS of 7.5 months (95% CI, 5.4 to not reached). CONCLUSION: iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical EGFR mutations, especially in EGFR exon20ins/nonclassical and HER2 mutations.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (10) , 893-902
Open AccessIzalontamab Brengitecan in Locally Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study
PURPOSE: To evaluate the safety and efficacy of izalontamab brengitecan (iza-bren) in patients with non–small cell lung cancer (NSCLC) harboring actionable genomic alterations (GAs) outside of classical epidermal growth factor receptor ( EGFR ) mutations. METHODS: Eligible patients had locally advanced or metastatic NSCLC with prespecific actionable GAs, had progressed after standard treatment and received no more than one previous line of chemotherapy. iza-bren was administered at the dose of 2.5 mg/kg once per day on days 1 and 8 of each 3-week cycle. The primary end point was safety. The secondary end points included objective response rate (ORR), disease control rate (DCR), and duration of response. The exploratory end points included progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 83 patients with NSCLC were enrolled in four cohorts: EGFR exon20ins/nonclassical mutations (n = 14), human epidermal growth factor receptor 2 ( HER2 ) mutation (n = 19), KRAS / BRAF / MET mutation (n = 26), and ALK / ROS1 / RET / NTRK fusion (n = 24). The most common grade ≥3 treatment-related adverse events (TRAEs) were thrombocytopenia (51.8%), anemia (44.6%), and neutropenia (43.4%). The most frequent nonhematologic TRAEs of all grades were nausea (49.4%), asthenia (45.8%), stomatitis (44.6%), and diarrhea (38.6%). One case of grade 2 interstitial lung disease was observed. The confirmed ORR was 39.7%, and the DCR was 85.9%. The median PFS was 7.0 months (95% CIs, 5.4 to 10.5), while OS data were immature. Patients with EGFR exon20ins or other nonclassical mutations achieved an ORR of 69.2% with a median PFS of 10.5 months (95% CI, 6.9 to not reached); the HER2 -mutant cohort had an ORR of 52.9% and a median PFS of 7.5 months (95% CI, 5.4 to not reached). CONCLUSION: iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical EGFR mutations, especially in EGFR exon20ins/nonclassical and HER2 mutations.
- Top Cited Papers
- 27 January 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (6) , 813-824
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
- 27 January 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (6) , 813-824
Top Cited PapersIzalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
- Open Access
Magnetic resonance‐guided split‐course hypo‐fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non–small cell lung cancer: A single arm, phase 2 study
Background: To evaluate the efficacy and safety of magnetic resonance (MR)‐guided split‐course hypo‐fractionated radiotherapy (hypo‐RT) with concurrent chemotherapy followed by consolidative immunotherapy (CIT) in locally advanced non–small cell lung cancer (LA‐NSCLC). Methods: In this phase 2 trial, patients with unresectable stage IIIA–C NSCLC (18–75 years old, Eastern Cooperative Oncology Group 0–1) received MR‐guided split‐course hypo‐RT (30 Gy in six fractions, repeated after 4 weeks for a total of 60 Gy) with concurrent weekly docetaxel (25 mg/m 2 ) and cisplatin (25 mg/m 2 ). The primary end point was progression‐free survival (PFS); secondary end points included overall survival (OS), objective response rate (ORR), and toxicities. Results: Between July 2020 and January 2023, 104 patients were enrolled with a median follow‐up of 34.4 months. Split‐course hypo‐concurrent chemoradiotherapy (CCRT) was completed in 101 (97.1%) patients, and 74 (71.2%) received CIT. The median PFS was 27.5 months (95% confidence interval [CI], 18.9–36.0 months), and the 1‐ and 2‐year PFS rates were 76.9% (95% CI, 69.2%–85.5%) and 54.7% (95% CI, 45.9%–65.1%), respectively. The 1‐ and 2‐year OS were 87.5% (95% CI, 81.4%–94.1%) and 65.3% (95% CI, 56.8%–75.2%), respectively. The most common grade 3–4 adverse event was lymphopenia (35.6%). Grade 2–3 pneumonitis was observed in eight patients (7.7%) during hypo‐CCRT and in seven patients (6.7%) during CIT. Grade 3 esophagitis occurred in three patients (2.8%), and one grade 5 hemoptysis was reported (0.9%). Conclusion: The MR‐guided split‐course hypo‐CCRT delivered at 5 Gy per fraction to a total dose of 60 Gy followed by CIT yielded encouraging survival outcomes with manageable toxicities in patients with LA‐NSCLC.
Open AccessMagnetic resonance‐guided split‐course hypo‐fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non–small cell lung cancer: A single arm, phase 2 study
Background: To evaluate the efficacy and safety of magnetic resonance (MR)‐guided split‐course hypo‐fractionated radiotherapy (hypo‐RT) with concurrent chemotherapy followed by consolidative immunotherapy (CIT) in locally advanced non–small cell lung cancer (LA‐NSCLC). Methods: In this phase 2 trial, patients with unresectable stage IIIA–C NSCLC (18–75 years old, Eastern Cooperative Oncology Group 0–1) received MR‐guided split‐course hypo‐RT (30 Gy in six fractions, repeated after 4 weeks for a total of 60 Gy) with concurrent weekly docetaxel (25 mg/m 2 ) and cisplatin (25 mg/m 2 ). The primary end point was progression‐free survival (PFS); secondary end points included overall survival (OS), objective response rate (ORR), and toxicities. Results: Between July 2020 and January 2023, 104 patients were enrolled with a median follow‐up of 34.4 months. Split‐course hypo‐concurrent chemoradiotherapy (CCRT) was completed in 101 (97.1%) patients, and 74 (71.2%) received CIT. The median PFS was 27.5 months (95% confidence interval [CI], 18.9–36.0 months), and the 1‐ and 2‐year PFS rates were 76.9% (95% CI, 69.2%–85.5%) and 54.7% (95% CI, 45.9%–65.1%), respectively. The 1‐ and 2‐year OS were 87.5% (95% CI, 81.4%–94.1%) and 65.3% (95% CI, 56.8%–75.2%), respectively. The most common grade 3–4 adverse event was lymphopenia (35.6%). Grade 2–3 pneumonitis was observed in eight patients (7.7%) during hypo‐CCRT and in seven patients (6.7%) during CIT. Grade 3 esophagitis occurred in three patients (2.8%), and one grade 5 hemoptysis was reported (0.9%). Conclusion: The MR‐guided split‐course hypo‐CCRT delivered at 5 Gy per fraction to a total dose of 60 Gy followed by CIT yielded encouraging survival outcomes with manageable toxicities in patients with LA‐NSCLC.
- Open Access
- 1 December 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases
The efficacy and prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) are poor. The third-generation EGFR-tyrosine kinase inhibitor proved to have better intracranial efficacy, which combined with anti-angiogenic drugs can further improve the efficacy. We conducted a single-arm, phase 2 clinical study (GASTO-1063) to explore the intracranial efficacy of aumolertinib plus anlotinib for NSCLC with BMs, with 87 patients enrolled. Median intracranial progression-free survival (PFS) was 30.2 months, median overall PFS was 22.5 months, and median overall survival was not reached. The intracranial objective response rate and intracranial disease control rate were 71.3% and 93.1%. Patients with exon 19 deletion or wild-type TP53 exhibited significantly longer intracranial PFS and PFS compared to those with exon 21 L858R mutation or mutated TP53. Aumolertinib plus anlotinib was effective and well-tolerated as first-line therapy in EGFR-mutant NSCLC patients with BMs. Trial Registration: ClinicalTrials.gov(identifier NCT04978753, registered July 20, 2021).
- 1 December 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessEfficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases
The efficacy and prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) are poor. The third-generation EGFR-tyrosine kinase inhibitor proved to have better intracranial efficacy, which combined with anti-angiogenic drugs can further improve the efficacy. We conducted a single-arm, phase 2 clinical study (GASTO-1063) to explore the intracranial efficacy of aumolertinib plus anlotinib for NSCLC with BMs, with 87 patients enrolled. Median intracranial progression-free survival (PFS) was 30.2 months, median overall PFS was 22.5 months, and median overall survival was not reached. The intracranial objective response rate and intracranial disease control rate were 71.3% and 93.1%. Patients with exon 19 deletion or wild-type TP53 exhibited significantly longer intracranial PFS and PFS compared to those with exon 21 L858R mutation or mutated TP53. Aumolertinib plus anlotinib was effective and well-tolerated as first-line therapy in EGFR-mutant NSCLC patients with BMs. Trial Registration: ClinicalTrials.gov(identifier NCT04978753, registered July 20, 2021).
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for melanoma cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for melanoma cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed the correlation between testosterone levels, prognosis and T cell infiltration
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed the correlation between testosterone levels, prognosis and T cell infiltration
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from N6-Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer
The detailed procedures of methods and eight figures are attached in supplementary.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from N6-Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer
The detailed procedures of methods and eight figures are attached in supplementary.